The effect of 3-(5-nitro-2-thienyl)-9-chloro-5-morpholin-4-yl[1,2,4]triazolo[4,3-c]quinazoline on cell growth, cell cycle, induction of DNA fragmentation, and activity of caspase 3 in murine leukemia L1210 cells and fibroblast NIH-3T3 cells
Quinazolines are multitarget agents, which have broad spectrum of biological activity, and some of them are now in cancer clinical testing. 3‐(5‐nitro‐2‐thienyl)‐9‐chloro‐5‐morpholin‐4‐yl[1,2,4]triazolo[4,3‐c]quinazoline is a new synthetically prepared derivative, which in our previous study showed...
Saved in:
Published in | Cell biochemistry and function Vol. 24; no. 6; pp. 519 - 530 |
---|---|
Main Authors | , , , , |
Format | Journal Article |
Language | English |
Published |
Chichester, UK
John Wiley & Sons, Ltd
01.11.2006
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Quinazolines are multitarget agents, which have broad spectrum of biological activity, and some of them are now in cancer clinical testing. 3‐(5‐nitro‐2‐thienyl)‐9‐chloro‐5‐morpholin‐4‐yl[1,2,4]triazolo[4,3‐c]quinazoline is a new synthetically prepared derivative, which in our previous study showed cytotoxic effects on cancer cell lines HeLa and B16. Quinazoline, at micromolar concentrations, induced morphological changes and necrosis of B16 cells, and at nanomolar concentrations it produced changes of F‐actin cytoskeleton. It did not cause changes in the cell cycle, did not induce apoptotic cell death in B16 cells, did not have a mutagenic effect, and did not even behave as a typical intercalating agent. Little significant reduction of tumor volume in intramuscular transplanted B16 cells was observed. The aim of the present study was to examine the cytotoxic effect of 3‐(5‐nitro‐2‐thienyl)‐9‐chloro‐5‐morpholin‐4‐yl[1,2,4]triazolo[4,3‐c]quinazoline on murine leukemia L1210 cells and fibroblast NIH‐3T3 cells. Induction of cell morphology and cell cycle changes, induction of apoptosis and caspase 3 activity were studied. Quinazoline acted cytotoxically on both cell lines. The sensitivity of leukemia L1210 cells to the quinazoline was higher than that of fibroblast NIH‐3T3. The IC100 was 12 µM for L1210 cells and 24 µM for NIH‐3T3 cells. No effect of quinazoline on the cell cycle profile of L1210 and NIH‐3T3 was detected, however, quinazoline induced an increase of the sub‐G0 cell fraction, apoptotic DNA fragmentation, and apoptotic morphological changes at a concentration of 12 µM. This quinazoline concentration induced caspase 3 activity. Our results demonstrated that induction of apoptotic cell death via activation of caspase 3 contributed to the cytotoxic effects of 3‐(5‐nitro‐2‐thienyl)‐9‐chloro‐5‐morpholin‐4‐yl[1,2,4]triazolo[4,3‐c]quinazoline in murine leukemia L1210 cells. Copyright © 2005 John Wiley & Sons, Ltd. |
---|---|
AbstractList | Quinazolines are multitarget agents, which have broad spectrum of biological activity, and some of them are now in cancer clinical testing. 3-(5-nitro-2- thienyl)-9-chloro-5-morpholin-4-yl[1,2,4]triazolo[4,3-c]quinazolin e is a new synthetically prepared derivative, which in our previous study showed cytotoxic effects on cancer cell lines HeLa and B16. Quinazoline, at micromolar concentrations, induced morphological changes and necrosis of B16 cells, and at nanomolar concentrations it produced changes of F-actin cytoskeleton. It did not cause changes in the cell cycle, did not induce apoptotic cell death in B16 cells, did not have a mutagenic effect, and did not even behave as a typical intercalating agent. Little significant reduction of tumor volume in intramuscular transplanted B16 cells was observed. The aim of the present study was to examine the cytotoxic effect of 3-(5-nitro-2-thienyl)-9-chloro-5- morpholin-4-yl[1,2,4]triazolo[4,3-c]quinazoline on murine leukemia L1210 cells and fibroblast NIH-3T3 cells. Induction of cell morphology and cell cycle changes, induction of apoptosis and caspase 3 activity were studied. Quinazoline acted cytotoxically on both cell lines. The sensitivity of leukemia L1210 cells to the quinazoline was higher than that of fibroblast NIH-3T3. The IC sub(100) was 12 mu M for L1210 cells and 24 mu M for NIH-3T3 cells. No effect of quinazoline on the cell cycle profile of L1210 and NIH-3T3 was detected, however, quinazoline induced an increase of the sub-G sub(0) cell fraction, apoptotic DNA fragmentation, and apoptotic morphological changes at a concentration of 12 mu M. This quinazoline concentration induced caspase 3 activity. Our results demonstrated that induction of apoptotic cell death via activation of caspase 3 contributed to the cytotoxic effects of 3-(5-nitro-2-thienyl)-9-chloro-5- morpholin-4-yl[1,2,4]triazolo[4,3-c]quinazoline in murine leukemia L1210 cells. Abstract Quinazolines are multitarget agents, which have broad spectrum of biological activity, and some of them are now in cancer clinical testing. 3‐(5‐nitro‐2‐thienyl)‐9‐chloro‐5‐morpholin‐4‐yl[1,2,4]triazolo[4,3‐c]quinazoline is a new synthetically prepared derivative, which in our previous study showed cytotoxic effects on cancer cell lines HeLa and B16. Quinazoline, at micromolar concentrations, induced morphological changes and necrosis of B16 cells, and at nanomolar concentrations it produced changes of F‐actin cytoskeleton. It did not cause changes in the cell cycle, did not induce apoptotic cell death in B16 cells, did not have a mutagenic effect, and did not even behave as a typical intercalating agent. Little significant reduction of tumor volume in intramuscular transplanted B16 cells was observed. The aim of the present study was to examine the cytotoxic effect of 3‐(5‐nitro‐2‐thienyl)‐9‐chloro‐5‐morpholin‐4‐yl[1,2,4]triazolo[4,3‐c]quinazoline on murine leukemia L1210 cells and fibroblast NIH‐3T3 cells. Induction of cell morphology and cell cycle changes, induction of apoptosis and caspase 3 activity were studied. Quinazoline acted cytotoxically on both cell lines. The sensitivity of leukemia L1210 cells to the quinazoline was higher than that of fibroblast NIH‐3T3. The IC 100 was 12 µM for L1210 cells and 24 µM for NIH‐3T3 cells. No effect of quinazoline on the cell cycle profile of L1210 and NIH‐3T3 was detected, however, quinazoline induced an increase of the sub‐G 0 cell fraction, apoptotic DNA fragmentation, and apoptotic morphological changes at a concentration of 12 µM. This quinazoline concentration induced caspase 3 activity. Our results demonstrated that induction of apoptotic cell death via activation of caspase 3 contributed to the cytotoxic effects of 3‐(5‐nitro‐2‐thienyl)‐9‐chloro‐5‐morpholin‐4‐yl[1,2,4]triazolo[4,3‐c]quinazoline in murine leukemia L1210 cells. Copyright © 2005 John Wiley & Sons, Ltd. Quinazolines are multitarget agents, which have broad spectrum of biological activity, and some of them are now in cancer clinical testing. 3-(5-nitro-2-thienyl)-9-chloro-5-morpholin-4-yl[1,2,4]triazolo[4,3-c]quinazoline is a new synthetically prepared derivative, which in our previous study showed cytotoxic effects on cancer cell lines HeLa and B16. Quinazoline, at micromolar concentrations, induced morphological changes and necrosis of B16 cells, and at nanomolar concentrations it produced changes of F-actin cytoskeleton. It did not cause changes in the cell cycle, did not induce apoptotic cell death in B16 cells, did not have a mutagenic effect, and did not even behave as a typical intercalating agent. Little significant reduction of tumor volume in intramuscular transplanted B16 cells was observed. The aim of the present study was to examine the cytotoxic effect of 3-(5-nitro-2-thienyl)-9-chloro-5-morpholin-4-yl[1,2,4]triazolo[4,3-c]quinazoline on murine leukemia L1210 cells and fibroblast NIH-3T3 cells. Induction of cell morphology and cell cycle changes, induction of apoptosis and caspase 3 activity were studied. Quinazoline acted cytotoxically on both cell lines. The sensitivity of leukemia L1210 cells to the quinazoline was higher than that of fibroblast NIH-3T3. The IC(100) was 12 microM for L1210 cells and 24 microM for NIH-3T3 cells. No effect of quinazoline on the cell cycle profile of L1210 and NIH-3T3 was detected, however, quinazoline induced an increase of the sub-G(0) cell fraction, apoptotic DNA fragmentation, and apoptotic morphological changes at a concentration of 12 microM. This quinazoline concentration induced caspase 3 activity. Our results demonstrated that induction of apoptotic cell death via activation of caspase 3 contributed to the cytotoxic effects of 3-(5-nitro-2-thienyl)-9-chloro-5-morpholin-4-yl[1,2,4]triazolo[4,3-c]quinazoline in murine leukemia L1210 cells. Quinazolines are multitarget agents, which have broad spectrum of biological activity, and some of them are now in cancer clinical testing. 3‐(5‐nitro‐2‐thienyl)‐9‐chloro‐5‐morpholin‐4‐yl[1,2,4]triazolo[4,3‐c]quinazoline is a new synthetically prepared derivative, which in our previous study showed cytotoxic effects on cancer cell lines HeLa and B16. Quinazoline, at micromolar concentrations, induced morphological changes and necrosis of B16 cells, and at nanomolar concentrations it produced changes of F‐actin cytoskeleton. It did not cause changes in the cell cycle, did not induce apoptotic cell death in B16 cells, did not have a mutagenic effect, and did not even behave as a typical intercalating agent. Little significant reduction of tumor volume in intramuscular transplanted B16 cells was observed. The aim of the present study was to examine the cytotoxic effect of 3‐(5‐nitro‐2‐thienyl)‐9‐chloro‐5‐morpholin‐4‐yl[1,2,4]triazolo[4,3‐c]quinazoline on murine leukemia L1210 cells and fibroblast NIH‐3T3 cells. Induction of cell morphology and cell cycle changes, induction of apoptosis and caspase 3 activity were studied. Quinazoline acted cytotoxically on both cell lines. The sensitivity of leukemia L1210 cells to the quinazoline was higher than that of fibroblast NIH‐3T3. The IC100 was 12 µM for L1210 cells and 24 µM for NIH‐3T3 cells. No effect of quinazoline on the cell cycle profile of L1210 and NIH‐3T3 was detected, however, quinazoline induced an increase of the sub‐G0 cell fraction, apoptotic DNA fragmentation, and apoptotic morphological changes at a concentration of 12 µM. This quinazoline concentration induced caspase 3 activity. Our results demonstrated that induction of apoptotic cell death via activation of caspase 3 contributed to the cytotoxic effects of 3‐(5‐nitro‐2‐thienyl)‐9‐chloro‐5‐morpholin‐4‐yl[1,2,4]triazolo[4,3‐c]quinazoline in murine leukemia L1210 cells. Copyright © 2005 John Wiley & Sons, Ltd. |
Author | Repický, A. Jantová, S. Letašiová, S. Ovádeková, R. Lakatoš, B. |
Author_xml | – sequence: 1 givenname: S surname: Jantova fullname: Jantova, S – sequence: 2 givenname: S surname: Letasiova fullname: Letasiova, S – sequence: 3 givenname: A surname: Repicky fullname: Repicky, A – sequence: 4 givenname: R surname: Ovadekova fullname: Ovadekova, R – sequence: 5 givenname: B surname: Lakatos fullname: Lakatos, B |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/16342136$$D View this record in MEDLINE/PubMed |
BookMark | eNp1kV1v0zAUhiM0xLqBxC9AvkJDioe_4iaXW2HdpFIkVD6kabIc117NHLuzE0b41fwEkrWCK66Oz_FzHlt6j7IDH7zOspcYnWKEyFtVm1NMKv4km2BUVRCVjB1kE0Q4hZyV7DA7Suk7QqjiFD3LDjGnjGDKJ9nv1UYDbYxWLQgGUHhSQG_bGCCB7cZq37s3sIJq48IwK2AT4nYTnPWQwd5d45zk7KaNVv4KLlyznEJ1c99ZP_bWaxA8UNo5cBvDQ7vJd43qldM5sH7dqdYOyPDyu-UZMFHeNtq3chzmQPo1kAPww7b9iCiZtjJpQIdN0HRx9Dvd3enGSrDABKNHfXpcNLaOoXYytWB5dQnpiu4un2dPjXRJv9jX4-zzxfvV7BIuPs6vZmcLqGhZcliboiq0Kk01lDUjaDhjNsWKIlYhjTFZ11OmCTecFJxJJQnVBtfcVKYuUEWPs9c77zaG-06nVjQ2jT-QXocuCYIwKSkpBvBkB6oYUoraiG20jYy9wEiM6YohXTGmO6Cv9s6ubvT6H7iPcwDgDniwTvf_FYnZ-cVeuOdtavXPv7yMd4JP6bQQX5dzMcdk-en8wzfxhf4BcPC-qQ |
CitedBy_id | crossref_primary_10_1016_j_jphotobiol_2010_09_007 crossref_primary_10_1016_j_jphotobiol_2015_11_014 crossref_primary_10_1016_j_molstruc_2024_137822 crossref_primary_10_1002_cbf_1421 crossref_primary_10_1021_jo900428j crossref_primary_10_3987_COM_10_12093 crossref_primary_10_1039_c3ra46796a crossref_primary_10_1007_s00216_009_2740_x crossref_primary_10_1007_s00604_008_0068_4 crossref_primary_10_1021_jo5013288 crossref_primary_10_1039_D2MD00023G crossref_primary_10_1021_jm400394s crossref_primary_10_4155_fmc_2017_0284 |
Cites_doi | 10.1097/00001813-199701000-00001 10.1016/S0016-5085(98)70312-9 10.2337/diabetes.48.3.609 10.1016/j.bcp.2004.06.006 10.1016/S0021-9258(19)52451-6 10.1023/B:APPT.0000012124.30095.09 10.1016/0006-2952(95)02156-6 10.1038/sj.bjc.6601873 10.1007/978-1-4615-0081-0_19 10.1046/j.1440-1827.2001.01204.x 10.1016/S1368-8375(03)00131-3 10.1002/jhet.5570290117 10.1135/cccc19911719 10.1097/00001813-200409000-00011 10.1007/BF02931453 10.1007/BF00689203 10.1002/ardp.19903231004 10.1021/jm00089a021 10.1007/s002800050608 10.1016/S1368-8375(98)00118-3 10.1158/0008-5472.CAN-04-1905 10.1097/01.ju.0000138524.18870.af 10.1093/jnci/82.9.749 10.1110/ps.8.3.467 10.1021/bi981881d 10.1038/sj.bjc.6602108 10.1016/S0014-827X(98)00002-0 10.1038/bjc.1998.747 10.1124/jpet.102.039651 |
ContentType | Journal Article |
Copyright | Copyright © 2005 John Wiley & Sons, Ltd. Copyright (c) 2005 John Wiley & Sons, Ltd. |
Copyright_xml | – notice: Copyright © 2005 John Wiley & Sons, Ltd. – notice: Copyright (c) 2005 John Wiley & Sons, Ltd. |
DBID | BSCLL CGR CUY CVF ECM EIF NPM AAYXX CITATION 7TM |
DOI | 10.1002/cbf.1296 |
DatabaseName | Istex Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef Nucleic Acids Abstracts |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef Nucleic Acids Abstracts |
DatabaseTitleList | Nucleic Acids Abstracts CrossRef MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Chemistry Biology |
EISSN | 1099-0844 |
EndPage | 530 |
ExternalDocumentID | 10_1002_cbf_1296 16342136 CBF1296 ark_67375_WNG_G12NRBMX_V |
Genre | article Research Support, Non-U.S. Gov't Journal Article |
GrantInformation_xml | – fundername: Ministry of Education of the Slovak Republic funderid: APVT‐20‐007304 |
GroupedDBID | --- .3N .GA .Y3 05W 0R~ 10A 1L6 1OB 1OC 1ZS 29B 31~ 33P 3SF 3WU 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5VS 66C 6J9 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAHHS AANLZ AAONW AASGY AAXRX AAZKR ABCQN ABCUV ABEML ABIJN ABPVW ABQWH ABXGK ACAHQ ACBWZ ACCFJ ACCZN ACGFO ACGFS ACGOF ACIWK ACMXC ACPOU ACPRK ACSCC ACXBN ACXQS ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADOZA ADXAS ADZMN ADZOD AEEZP AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFFPM AFGKR AFPWT AFRAH AFZJQ AHBTC AIACR AIAGR AITYG AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN AMBMR AMYDB ASPBG ATUGU AVWKF AZBYB AZFZN AZVAB BAFTC BDRZF BFHJK BHBCM BLYAC BMXJE BROTX BRXPI BSCLL BY8 C45 CS3 D-6 D-7 D-E D-F DCZOG DPXWK DR1 DR2 DRFUL DRMAN DRSTM DU5 EBD EBS EJD EMOBN F00 F01 F04 F5P FEDTE FUBAC G-S G.N GNP GODZA H.X HF~ HGLYW HHY HHZ HVGLF HZ~ IX1 J0M JPC KBYEO KQQ LATKE LAW LC2 LC3 LEEKS LH4 LH6 LITHE LOXES LP6 LP7 LUTES LW6 LYRES MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NDZJH NF~ O66 O9- OIG OVD P2P P2W P2X P2Z P4B P4D PALCI Q.N Q11 QB0 QRW R.K RBB RIWAO RJQFR ROL RWI RX1 RYL SAMSI SUPJJ SV3 TEORI UB1 V2E V8K W8V W99 WBKPD WH7 WIB WIH WIJ WIK WJL WNSPC WOHZO WQJ WRC WSB WXI WXSBR WYISQ XG1 XPP XV2 ZZTAW ~IA ~WT CGR CUY CVF ECM EIF NPM AAYXX CITATION 7TM |
ID | FETCH-LOGICAL-c3886-bf595ec8f995ed420ec81471c30490e112db74e26f62564aca23ef1b6f9fb5093 |
IEDL.DBID | DR2 |
ISSN | 0263-6484 |
IngestDate | Fri Aug 16 07:20:49 EDT 2024 Fri Aug 23 01:49:18 EDT 2024 Sat Sep 28 07:48:47 EDT 2024 Sat Aug 24 00:55:55 EDT 2024 Wed Oct 30 09:48:09 EDT 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 6 |
Language | English |
License | Copyright (c) 2005 John Wiley & Sons, Ltd. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c3886-bf595ec8f995ed420ec81471c30490e112db74e26f62564aca23ef1b6f9fb5093 |
Notes | Ministry of Education of the Slovak Republic - No. APVT-20-007304 istex:731B420174A111D0213CECE013A0259759658A0B ArticleID:CBF1296 ark:/67375/WNG-G12NRBMX-V ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
PMID | 16342136 |
PQID | 20128325 |
PQPubID | 23462 |
PageCount | 12 |
ParticipantIDs | proquest_miscellaneous_20128325 crossref_primary_10_1002_cbf_1296 pubmed_primary_16342136 wiley_primary_10_1002_cbf_1296_CBF1296 istex_primary_ark_67375_WNG_G12NRBMX_V |
PublicationCentury | 2000 |
PublicationDate | November/December 2006 |
PublicationDateYYYYMMDD | 2006-11-01 |
PublicationDate_xml | – month: 11 year: 2006 text: November/December 2006 |
PublicationDecade | 2000 |
PublicationPlace | Chichester, UK |
PublicationPlace_xml | – name: Chichester, UK – name: England |
PublicationTitle | Cell biochemistry and function |
PublicationTitleAlternate | Cell Biochem. Funct |
PublicationYear | 2006 |
Publisher | John Wiley & Sons, Ltd |
Publisher_xml | – name: John Wiley & Sons, Ltd |
References | Kaye SB. New antimetabolites in cancer chemotherapy and their clinical impact. Br J Cancer 1998; 78: 1-7. Austin PF, Cook BL, Niederhoff RA, Manson SR, Coplen DE, Weintraub SJ. Inhibition of mitogenic signaling and induction of apoptosis in human bladder smooth muscle cells treated with doxazosin. J Urol 2004; 4: 1662-1665. Špirková K, Stankovský Š, Horňáček J. Amidinoyl isothiocyanates in the synthesis of condensed quinazolines. Preparation of 3-aryl-5,9-disubstituted s-triazolo[4,3-c] quinazolines and their [1,5-c]isomers. Chem Paper 1993; 6: 382-385. Kornet MJ. Synthesis and anticonvulsant activity of 3-alkyl-3,4-dihydro-2(1H)-quinazolinones. J Heterocyclic Chem 1992; 29: 103-105. Loriga M, Vitale G, Paglietti G. Quinoxaline chemistry. Part 9. Quinoxaline analogues of trimetrexate (TMQ) and 10-propargyl-5,8-dideazafolic acid (CB3717) and its precursors. Synthesis and evaluation of in vitro anticancer activity. Farmaco 1998; 53: 139-149. Pomarnacka E, Angielski S, Hoppe A. Derivatives of 4-chloro-5-sulfanoyl-benzoic acid. 8. Synthesis and diuretic activity of pyrazole[3,2-b] quinazoline and 1-benzoylpyrazole derivatives. Acta Polon Pharm 1984; 41: 141-151. Polshakov VI, Birdsall B, Frenkiel TA, Gargaro AR, Feeney J. Structure and dynamics in solution of the complex of Lactobacillus casei dihydrofolate reductase with the new lipophilic antifolate drug trimetrexate. Protein Sci 1999; 8: 467-481. Takemura Y, Jackman A. Folate-based thymidylate synthase inhibitors in cancer chemotherapy. Anti-Cancer Drugs 1997; 8: 3-16. Tonkinson JL, Marder P, Andis SL, et al. Cell cycle effects of antifolate antimetabolites: implications for cytotoxicity and cytostatis. Cancer Chemother Pharmacol 1997; 39: 521-531. Fumarola C, Guidotii GG. Stress-induced apoptosi: toward a symmetry with receptor-mediated cell death. Apoptosis 2004; 9: 77-82. Kimoto T, Hino K, Koya-Miyata S, et al. Cell differentiation and apoptosis of monocytic and promyelocytic leukemia cells (U-937 and HL-60) by tryptanthrin, an active ingredient of Polygonum tinctorium Lour. Pathol Int 2001; 5: 315-325. Grunwald V, Hidalgo M. Development of the epidermal growth factor receptor inhibitor tarceva (OSI-774). Edv Exp Med Biol 2003; 532: 235-246. Shimoyama M, Ogino K, Tanaka Y, Ikeda T, Hisatome I. Hemodynamic basic for the acute cardiac effects of troglitazone in isolated perfused rat hearts. Diabetes 1999; 3: 609-615. Naithani PK, Palit G, Srivastava VK, Shanker K. 2,3-Disubstituted quinazolinones and their antiparkinsonian activity. Ind J Chem Sect B, Org Chem Incl Med Chem 1989; 28: 745-750. Karnes WE, Weller SG, Adjei PN, et al. Inhibition of epidermal growth factor receptor kinase induces protease-dependent apotosis in human colon cancer cells. Gastroenterology 1998; 5: 930-939. Abdel-Rahman TM. Synthesis of some new biologically active 2,3-disubstituted quinazolin-4-ones. Boll Chim Farm 1998; 137: 43-47. Faust RA, Tawfic S, Davis AT, Ahmed K. Apoptosis and growth inhibition of head and neck tumor cell line induced by epidermal growth factor receptor tyrosine kinase inhibitor. Oral Oncol 1999; 35: 290-295. Bos M, Mendelsohn J, Kim YM, Albanell J, Fry DW, Baselga J. PD153035, a tyrosine kinase inhibitor, prevents epidermal growth factor receptor activation and inhibits growth of cancer cells in a receptor number-dependent manner. Clin Cancer Res 1997; 3: 2099-2106. Sorenson CHM, Barry MA, Eastman A. Analysis of events associated with cell cycle arrest at G2 phase and cell death induced by cisplatin. J Natl Cancer Inst 1990; 82: 749-754. Chang GCH, Hsu SL, Tsai JR, et al. Molecular mechanism of ZD1839-induced G1-cell cycle arrest and apoptosis in human lung adenocarcinoma A549 cells. Biochem Pharm 2004; 68: 1453-1464. Ciardiello F, Caputo R, Bianco R, et al. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin Cancer Res 2000; 6: 2053-2063. Sandstrom M, Johansson M, Andersson U, Bergh A, Bergenheim A, Henriksson R. The tyrosine kinase inhibitor ZD6474 inhibitors tumour growth in an intracerebral rat glioma model. Br J Cancer 2004; 6: 1174-1180. Scott CW, Sobotka-Briner C, Wilkins DE, et al. Novel small molecule inhibitors of caspase 3 block cellular and biochemical features of apoptosis. J Pharmacol Exp Ther 2003; 1: 433-440. Shintani S, Li C, Mihara M, et al. Gefitinib (Iressa, ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, up-regulates p27KIP1 and induces G1 arrest in oral squamous cell carcinoma cell lines. Oral Onco 2004; 1: 43-51. Jantovnnná S, Urbančíková M,Maliar T, et al. Biological activity of some 4-anilinoquinazolines: cytotoxic, genotoxic and antiprotease effects, induction of necrosis and changes of actin cytoskeleton. Neoplasma 2001; 1: 52-60. Špirková K, Stankovský Š. Amidinoyl isothiocyanates in the synthesis of condensed quinazolines. Preparation of 3-aryl-5,9-disubstituted s-triazolo[4,3-c]quinazolines. Collect Czech Chem Commun 1991; 56: 1719-1724. Park JK, Lee SH, Kang JH, Nishio K, Saijo N, Kuh HJ. Synergistic interaction between gefitinib (Iressa, ZD1839) and oarlitaxel against human gastric carcinoma cells. Anticancer Drugs 2004; 8: 809-818. Chang GC, Hsu SL, Tsai JR, et al. Molecular mechanism of ZD1839-induced G1-cell cycle arrest and apoptosis in human lung adenocarcinoma A549 cells. Biochem Pharmacol 2004; 7: 1453-1464. Ranson M. Epidermal growth factor receptor tyrosine kinase inhibitors. Br J Cancer 2004; 90: 2250-2255. Narla RK, Liu XP, Myers DE, Uckun FM. 4-(3α-Bromo-4'hydroxylphenyl)-amino-6,7-dimethoxyquinazoline: a novel quinazoline derivative with potent cytotoxic activity against human glioblastoma cells. Clin Cancer Res 1998; 4: 1405-1414. Karnes Jr WE, Weller SG, Adjei PN, et al. Inhibition of epidermal growth factor receptor kinase induces protease-dependent apoptosis in human colon cancer cell. Gastroenterology 1998; 114: 930-939. Farghaly AM, Chaaban I, Khalil MA, Bekhit AA. Non-steroidal antiinflammatory agents. Synthesis of novel 2-pyrazolyl-4(3)-quinazolinones. Arch Pharmacol 1990; 323: 833-836. Kimoto T, Hino K, Koya-Miyata S, et al. Cell differentiation and apoptosis of monocytic and promyeloytic leukemia cells (U-937 and HL-60) by tryptanthin, an active ingredient of Polygonum tinctorium Lour. Pathol Int 2001; 51: 315-325. Sotelo-Mundo RR, Ciesla J, Dzík JM, et al. Crystal structures of rat thymidylate synthase inhibited by Tomudex, a potent anticancer drug. Biochemistry 1990; 38: 1087-1094. Jantová S, Ovádeková R, Letašiová S, Špirková K, Stankovský Š. Antimicrobial activity of some substituted triazoloquinazolines. Folia Microbiol 2005; 2: 90-94. Yamagishi M, Yamada Y, Ozaki K, et al. Biological activities and quantitative structure-activity relationships of spiro[imidazolidine-4-4'-(1H) quinazoline]-2,2,5(H)-triones as aldose reductase inhibitors. J Med Chem 1992; 35: 2085-2094. Yang JS, Hour MJ, Kuo SC, Huang LJ, Lee MR. Selective induction of G2/M arrest and apoptosis in HL-60 by a potent anticancer agent, HMJ-38. Anticancer Res 2004; 24: 1769-1778. Modjtahedi H, Affleck K, Stubberfield C, Dean C. EGFR blockade by tyrosine kinase inhibitor or monoclonal antibody inhibits growth, directs terminal differentiation and induces apoptosis in the human squamous cell carcinoma HN5. Int J Oncol 1998: 13: 335-342. Yang JS, Hour MJ, Kuo SC, Huang LJ, Lee MR. Selective induction of G2/M arrest and apoptosis in HL-60 by a potent anticancer agent, HMJ-38. Anticancer Res 2004; 3a: 1769-1778. Chiang CF, Son EL, Wu GJ. Oral treatment of the TRAMP mice with doxazosin suppresses prostate tumor growth and metastasis. Prostate 2005; 4: 1778-1783. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951; 143: 265. Janmaat ML, Kruyt FAE, Rodriguez JA, Giaccone G. Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways. Clin Cancer Res 2003; 9: 2316-2326. Holden SA, Teicher BA, Robinson MF, Northey D. Rosowsky A. Antifolates can potentiate topoisomerase II inhibitors in vitro and in vivo. Cancer Chemother 1995; 36: 165-171. Tracy S, Mukohara T, Hansen M, Meyerson M, Johnson BE, Janne PA. Gefitinib induces apoptosis in the EGFR L858R non-small-cell lung cancer cell line H3255. Cancer Res 2004; 20: 7241-7244. Hamel E, Lin CM, Plowman J, Wang H, Lee KH, Paull KD. Antitumour 2,3-dihydro-2-(aryl)-4(1H)-quinazolinone derivatives. Interactions with tubulin. Biochem Pharmacol 1996; 51: 53-59. 1984; 41 2004; 20 1990; 323 1991; 56 2000; 6 1990; 38 1995; 36 2004; 8 2004; 7 2004; 68 2004; 9 2004; 24 2004; 4 2004; 6 1996; 51 2004; 3a 1998; 137 1992; 35 2005 1999; 3 1951; 143 1998; 114 2004; 1 2004; 90 1999; 8 2003; 532 1997; 3 1990; 82 1989; 28 1997; 8 1993; 6 1963; 1 2001; 5 2003; 9 1999; 35 1992; 29 2005; 4 1997; 39 2001; 1 2005; 2 2003; 1 1998; 5 1998; 53 1998; 4 1998; 78 2001; 51 1998; 13 Bos M (e_1_2_1_16_2) 1997; 3 Narla RK (e_1_2_1_30_2) 1998; 4 Modjtahedi H (e_1_2_1_20_2) 1998; 13 Lowry OH (e_1_2_1_27_2) 1951; 143 Špirková K (e_1_2_1_24_2) 1993; 6 Letašiová S (e_1_2_1_26_2) 2005 e_1_2_1_40_2 e_1_2_1_22_2 e_1_2_1_23_2 e_1_2_1_44_2 Wiseloge FW (e_1_2_1_2_2) 1963 e_1_2_1_43_2 e_1_2_1_21_2 e_1_2_1_42_2 Ciardiello F (e_1_2_1_32_2) 2000; 6 e_1_2_1_25_2 e_1_2_1_46_2 Naithani PK (e_1_2_1_9_2) 1989; 28 Pomarnacka E (e_1_2_1_5_2) 1984; 41 e_1_2_1_28_2 e_1_2_1_29_2 Sandstrom M (e_1_2_1_38_2) 2004; 6 Janmaat ML (e_1_2_1_45_2) 2003; 9 e_1_2_1_6_2 Jantovnnná S (e_1_2_1_12_2) 2001; 1 e_1_2_1_7_2 e_1_2_1_4_2 e_1_2_1_11_2 e_1_2_1_34_2 Yang JS (e_1_2_1_41_2) 2004; 3 e_1_2_1_33_2 e_1_2_1_10_2 e_1_2_1_31_2 e_1_2_1_15_2 Abdel‐Rahman TM (e_1_2_1_3_2) 1998; 137 e_1_2_1_37_2 e_1_2_1_13_2 e_1_2_1_36_2 Yang JS (e_1_2_1_47_2) 2004; 24 e_1_2_1_14_2 e_1_2_1_35_2 e_1_2_1_19_2 e_1_2_1_8_2 e_1_2_1_17_2 Chiang CF (e_1_2_1_48_2) 2005; 4 e_1_2_1_18_2 e_1_2_1_39_2 |
References_xml | – volume: 29 start-page: 103 year: 1992 end-page: 105 article-title: Synthesis and anticonvulsant activity of 3‐alkyl‐3,4‐dihydro‐2(1H)‐quinazolinones publication-title: J Heterocyclic Chem – volume: 51 start-page: 315 year: 2001 end-page: 325 article-title: Cell differentiation and apoptosis of monocytic and promyeloytic leukemia cells (U‐937 and HL‐60) by tryptanthin, an active ingredient of Lour publication-title: Pathol Int – volume: 4 start-page: 1662 year: 2004 end-page: 1665 article-title: Inhibition of mitogenic signaling and induction of apoptosis in human bladder smooth muscle cells treated with doxazosin publication-title: J Urol – volume: 9 start-page: 77 year: 2004 end-page: 82 article-title: Stress‐induced apoptosi: toward a symmetry with receptor‐mediated cell death publication-title: Apoptosis – volume: 9 start-page: 2316 year: 2003 end-page: 2326 article-title: Response to epidermal growth factor receptor inhibitors in non‐small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal‐regulated kinase or Akt kinase pathways publication-title: Clin Cancer Res – volume: 39 start-page: 521 year: 1997 end-page: 531 article-title: Cell cycle effects of antifolate antimetabolites: implications for cytotoxicity and cytostatis publication-title: Cancer Chemother Pharmacol – volume: 82 start-page: 749 year: 1990 end-page: 754 article-title: Analysis of events associated with cell cycle arrest at G phase and cell death induced by cisplatin publication-title: J Natl Cancer Inst – volume: 532 start-page: 235 year: 2003 end-page: 246 article-title: Development of the epidermal growth factor receptor inhibitor tarceva (OSI‐774) publication-title: Edv Exp Med Biol – volume: 6 start-page: 1174 year: 2004 end-page: 1180 article-title: The tyrosine kinase inhibitor ZD6474 inhibitors tumour growth in an intracerebral rat glioma model publication-title: Br J Cancer – volume: 38 start-page: 1087 year: 1990 end-page: 1094 article-title: Crystal structures of rat thymidylate synthase inhibited by Tomudex, a potent anticancer drug publication-title: Biochemistry – volume: 51 start-page: 53 year: 1996 end-page: 59 article-title: Antitumour 2,3‐dihydro‐2‐(aryl)‐4(1H)‐quinazolinone derivatives. Interactions with tubulin publication-title: Biochem Pharmacol – volume: 1 start-page: 43 year: 2004 end-page: 51 article-title: Gefitinib (Iressa, ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, up‐regulates p27KIP1 and induces G arrest in oral squamous cell carcinoma cell lines publication-title: Oral Onco – volume: 4 start-page: 1405 year: 1998 end-page: 1414 article-title: 4‐(3α‐Bromo‐4'hydroxylphenyl)‐amino‐6,7‐dimethoxyquinazoline: a novel quinazoline derivative with potent cytotoxic activity against human glioblastoma cells publication-title: Clin Cancer Res – volume: 1 start-page: 433 year: 2003 end-page: 440 article-title: Novel small molecule inhibitors of caspase 3 block cellular and biochemical features of apoptosis publication-title: J Pharmacol Exp Ther – volume: 8 start-page: 467 year: 1999 end-page: 481 article-title: Structure and dynamics in solution of the complex of dihydrofolate reductase with the new lipophilic antifolate drug trimetrexate publication-title: Protein Sci – volume: 323 start-page: 833 year: 1990 end-page: 836 article-title: Non‐steroidal antiinflammatory agents. Synthesis of novel 2‐pyrazolyl‐4(3)‐quinazolinones publication-title: Arch Pharmacol – volume: 8 start-page: 3 year: 1997 end-page: 16 article-title: Folate‐based thymidylate synthase inhibitors in cancer chemotherapy publication-title: Anti‐Cancer Drugs – volume: 3a start-page: 1769 year: 2004 end-page: 1778 article-title: Selective induction of G /M arrest and apoptosis in HL‐60 by a potent anticancer agent, HMJ‐38 publication-title: Anticancer Res – volume: 114 start-page: 930 year: 1998 end-page: 939 article-title: Inhibition of epidermal growth factor receptor kinase induces protease‐dependent apoptosis in human colon cancer cell publication-title: Gastroenterology – volume: 5 start-page: 930 year: 1998 end-page: 939 article-title: Inhibition of epidermal growth factor receptor kinase induces protease‐dependent apotosis in human colon cancer cells publication-title: Gastroenterology – volume: 24 start-page: 1769 year: 2004 end-page: 1778 article-title: Selective induction of G /M arrest and apoptosis in HL‐60 by a potent anticancer agent, HMJ‐38 publication-title: Anticancer Res – volume: 35 start-page: 2085 year: 1992 end-page: 2094 article-title: Biological activities and quantitative structure–activity relationships of spiro[imidazolidine‐4‐4'‐(1H) quinazoline]‐2,2,5(H)‐triones as aldose reductase inhibitors publication-title: J Med Chem – volume: 1 start-page: 304 year: 1963 – volume: 3 start-page: 609 year: 1999 end-page: 615 article-title: Hemodynamic basic for the acute cardiac effects of troglitazone in isolated perfused rat hearts publication-title: Diabetes – volume: 137 start-page: 43 year: 1998 end-page: 47 article-title: Synthesis of some new biologically active 2,3‐disubstituted quinazolin‐4‐ones publication-title: Boll Chim Farm – volume: 3 start-page: 2099 year: 1997 end-page: 2106 article-title: PD153035, a tyrosine kinase inhibitor, prevents epidermal growth factor receptor activation and inhibits growth of cancer cells in a receptor number‐dependent manner publication-title: Clin Cancer Res – volume: 13 start-page: 335 year: 1998 end-page: 342 article-title: EGFR blockade by tyrosine kinase inhibitor or monoclonal antibody inhibits growth, directs terminal differentiation and induces apoptosis in the human squamous cell carcinoma HN5 publication-title: Int J Oncol – volume: 1 start-page: 52 year: 2001 end-page: 60 article-title: Biological activity of some 4‐anilinoquinazolines: cytotoxic, genotoxic and antiprotease effects, induction of necrosis and changes of actin cytoskeleton publication-title: Neoplasma – volume: 8 start-page: 809 year: 2004 end-page: 818 article-title: Synergistic interaction between gefitinib (Iressa, ZD1839) and oarlitaxel against human gastric carcinoma cells publication-title: Anticancer Drugs – volume: 53 start-page: 139 year: 1998 end-page: 149 article-title: Quinoxaline chemistry. Part 9. Quinoxaline analogues of trimetrexate (TMQ) and 10‐propargyl‐5,8‐dideazafolic acid (CB3717) and its precursors. Synthesis and evaluation of anticancer activity publication-title: Farmaco – volume: 6 start-page: 382 year: 1993 end-page: 385 article-title: Amidinoyl isothiocyanates in the synthesis of condensed quinazolines. Preparation of 3‐aryl‐5,9‐disubstituted ‐triazolo[4,3 ] quinazolines and their [1,5 ]isomers publication-title: Chem Paper – volume: 28 start-page: 745 year: 1989 end-page: 750 article-title: 2,3‐Disubstituted quinazolinones and their antiparkinsonian activity publication-title: Ind J Chem Sect B, Org Chem Incl Med Chem – volume: 78 start-page: 1 year: 1998 end-page: 7 article-title: New antimetabolites in cancer chemotherapy and their clinical impact publication-title: Br J Cancer – volume: 5 start-page: 315 year: 2001 end-page: 325 article-title: Cell differentiation and apoptosis of monocytic and promyelocytic leukemia cells (U‐937 and HL‐60) by tryptanthrin, an active ingredient of Lour publication-title: Pathol Int – volume: 68 start-page: 1453 year: 2004 end-page: 1464 article-title: Molecular mechanism of ZD1839‐induced G ‐cell cycle arrest and apoptosis in human lung adenocarcinoma A549 cells publication-title: Biochem Pharm – volume: 35 start-page: 290 year: 1999 end-page: 295 article-title: Apoptosis and growth inhibition of head and neck tumor cell line induced by epidermal growth factor receptor tyrosine kinase inhibitor publication-title: Oral Oncol – volume: 41 start-page: 141 year: 1984 end-page: 151 article-title: Derivatives of 4‐chloro‐5‐sulfanoyl‐benzoic acid. 8. Synthesis and diuretic activity of pyrazole[3,2‐ ] quinazoline and 1‐benzoylpyrazole derivatives publication-title: Acta Polon Pharm – volume: 36 start-page: 165 year: 1995 end-page: 171 article-title: Antifolates can potentiate topoisomerase II inhibitors and publication-title: Cancer Chemother – volume: 143 start-page: 265 year: 1951 article-title: Protein measurement with the Folin phenol reagent publication-title: J Biol Chem – volume: 20 start-page: 7241 year: 2004 end-page: 7244 article-title: Gefitinib induces apoptosis in the EGFR L858R non‐small‐cell lung H3255 publication-title: Cancer Res – volume: 2 start-page: 90 year: 2005 end-page: 94 article-title: Antimicrobial activity of some substituted triazoloquinazolines publication-title: Folia Microbiol – start-page: 74 year: 2005 – volume: 7 start-page: 1453 year: 2004 end-page: 1464 article-title: Molecular mechanism of ZD1839‐induced G ‐cell cycle arrest and apoptosis in human lung adenocarcinoma A549 cells publication-title: Biochem Pharmacol – volume: 4 start-page: 1778 year: 2005 end-page: 1783 article-title: Oral treatment of the TRAMP mice with doxazosin suppresses prostate tumor growth and metastasis publication-title: Prostate – volume: 90 start-page: 2250 year: 2004 end-page: 2255 article-title: Epidermal growth factor receptor tyrosine kinase inhibitors publication-title: Br J Cancer – volume: 56 start-page: 1719 year: 1991 end-page: 1724 article-title: Amidinoyl isothiocyanates in the synthesis of condensed quinazolines. Preparation of 3‐aryl‐5,9‐disubstituted ‐triazolo[4,3‐ ]quinazolines publication-title: Collect Czech Chem Commun – volume: 6 start-page: 2053 year: 2000 end-page: 2063 article-title: Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD‐1839 (Iressa), an epidermal growth factor receptor‐selective tyrosine kinase inhibitor publication-title: Clin Cancer Res – volume: 6 start-page: 2053 year: 2000 ident: e_1_2_1_32_2 article-title: Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD‐1839 (Iressa), an epidermal growth factor receptor‐selective tyrosine kinase inhibitor publication-title: Clin Cancer Res contributor: fullname: Ciardiello F – volume: 41 start-page: 141 year: 1984 ident: e_1_2_1_5_2 article-title: Derivatives of 4‐chloro‐5‐sulfanoyl‐benzoic acid. 8. Synthesis and diuretic activity of pyrazole[3,2‐b] quinazoline and 1‐benzoylpyrazole derivatives publication-title: Acta Polon Pharm contributor: fullname: Pomarnacka E – ident: e_1_2_1_18_2 doi: 10.1097/00001813-199701000-00001 – ident: e_1_2_1_29_2 doi: 10.1016/S0016-5085(98)70312-9 – volume: 6 start-page: 382 year: 1993 ident: e_1_2_1_24_2 article-title: Amidinoyl isothiocyanates in the synthesis of condensed quinazolines. Preparation of 3‐aryl‐5,9‐disubstituted s‐triazolo[4,3‐c] quinazolines and their [1,5‐c]isomers publication-title: Chem Paper contributor: fullname: Špirková K – ident: e_1_2_1_7_2 doi: 10.2337/diabetes.48.3.609 – ident: e_1_2_1_37_2 doi: 10.1016/j.bcp.2004.06.006 – start-page: 74 volume-title: Abstract of XXIII. Xenobiochemic Symposium in Valtice year: 2005 ident: e_1_2_1_26_2 contributor: fullname: Letašiová S – volume: 143 start-page: 265 year: 1951 ident: e_1_2_1_27_2 article-title: Protein measurement with the Folin phenol reagent publication-title: J Biol Chem doi: 10.1016/S0021-9258(19)52451-6 contributor: fullname: Lowry OH – ident: e_1_2_1_42_2 doi: 10.1023/B:APPT.0000012124.30095.09 – ident: e_1_2_1_19_2 doi: 10.1016/0006-2952(95)02156-6 – ident: e_1_2_1_14_2 doi: 10.1038/sj.bjc.6601873 – ident: e_1_2_1_39_2 doi: 10.1007/978-1-4615-0081-0_19 – ident: e_1_2_1_33_2 doi: 10.1046/j.1440-1827.2001.01204.x – ident: e_1_2_1_34_2 doi: 10.1016/S1368-8375(03)00131-3 – volume: 3 start-page: 2099 year: 1997 ident: e_1_2_1_16_2 article-title: PD153035, a tyrosine kinase inhibitor, prevents epidermal growth factor receptor activation and inhibits growth of cancer cells in a receptor number‐dependent manner publication-title: Clin Cancer Res contributor: fullname: Bos M – ident: e_1_2_1_28_2 doi: 10.1016/j.bcp.2004.06.006 – ident: e_1_2_1_6_2 doi: 10.1002/jhet.5570290117 – ident: e_1_2_1_23_2 doi: 10.1135/cccc19911719 – volume: 4 start-page: 1405 year: 1998 ident: e_1_2_1_30_2 article-title: 4‐(3α‐Bromo‐4'hydroxylphenyl)‐amino‐6,7‐dimethoxyquinazoline: a novel quinazoline derivative with potent cytotoxic activity against human glioblastoma cells publication-title: Clin Cancer Res contributor: fullname: Narla RK – volume: 9 start-page: 2316 year: 2003 ident: e_1_2_1_45_2 article-title: Response to epidermal growth factor receptor inhibitors in non‐small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal‐regulated kinase or Akt kinase pathways publication-title: Clin Cancer Res contributor: fullname: Janmaat ML – volume: 4 start-page: 1778 year: 2005 ident: e_1_2_1_48_2 article-title: Oral treatment of the TRAMP mice with doxazosin suppresses prostate tumor growth and metastasis publication-title: Prostate contributor: fullname: Chiang CF – volume: 137 start-page: 43 year: 1998 ident: e_1_2_1_3_2 article-title: Synthesis of some new biologically active 2,3‐disubstituted quinazolin‐4‐ones publication-title: Boll Chim Farm contributor: fullname: Abdel‐Rahman TM – volume: 28 start-page: 745 year: 1989 ident: e_1_2_1_9_2 article-title: 2,3‐Disubstituted quinazolinones and their antiparkinsonian activity publication-title: Ind J Chem Sect B, Org Chem Incl Med Chem contributor: fullname: Naithani PK – ident: e_1_2_1_44_2 doi: 10.1046/j.1440-1827.2001.01204.x – volume: 13 start-page: 335 year: 1998 ident: e_1_2_1_20_2 article-title: EGFR blockade by tyrosine kinase inhibitor or monoclonal antibody inhibits growth, directs terminal differentiation and induces apoptosis in the human squamous cell carcinoma HN5 publication-title: Int J Oncol contributor: fullname: Modjtahedi H – volume: 3 start-page: 1769 year: 2004 ident: e_1_2_1_41_2 article-title: Selective induction of G2/M arrest and apoptosis in HL‐60 by a potent anticancer agent, HMJ‐38 publication-title: Anticancer Res contributor: fullname: Yang JS – ident: e_1_2_1_43_2 doi: 10.1016/S0016-5085(98)70312-9 – ident: e_1_2_1_35_2 doi: 10.1097/00001813-200409000-00011 – ident: e_1_2_1_25_2 doi: 10.1007/BF02931453 – ident: e_1_2_1_21_2 doi: 10.1007/BF00689203 – volume: 24 start-page: 1769 year: 2004 ident: e_1_2_1_47_2 article-title: Selective induction of G2/M arrest and apoptosis in HL‐60 by a potent anticancer agent, HMJ‐38 publication-title: Anticancer Res contributor: fullname: Yang JS – ident: e_1_2_1_4_2 doi: 10.1002/ardp.19903231004 – ident: e_1_2_1_17_2 doi: 10.1021/jm00089a021 – ident: e_1_2_1_13_2 doi: 10.1007/s002800050608 – ident: e_1_2_1_31_2 doi: 10.1016/S1368-8375(98)00118-3 – ident: e_1_2_1_36_2 doi: 10.1158/0008-5472.CAN-04-1905 – volume: 1 start-page: 52 year: 2001 ident: e_1_2_1_12_2 article-title: Biological activity of some 4‐anilinoquinazolines: cytotoxic, genotoxic and antiprotease effects, induction of necrosis and changes of actin cytoskeleton publication-title: Neoplasma contributor: fullname: Jantovnnná S – ident: e_1_2_1_40_2 doi: 10.1097/01.ju.0000138524.18870.af – ident: e_1_2_1_8_2 doi: 10.1093/jnci/82.9.749 – ident: e_1_2_1_15_2 doi: 10.1110/ps.8.3.467 – ident: e_1_2_1_11_2 doi: 10.1021/bi981881d – volume: 6 start-page: 1174 year: 2004 ident: e_1_2_1_38_2 article-title: The tyrosine kinase inhibitor ZD6474 inhibitors tumour growth in an intracerebral rat glioma model publication-title: Br J Cancer doi: 10.1038/sj.bjc.6602108 contributor: fullname: Sandstrom M – ident: e_1_2_1_10_2 doi: 10.1016/S0014-827X(98)00002-0 – ident: e_1_2_1_22_2 doi: 10.1038/bjc.1998.747 – ident: e_1_2_1_46_2 doi: 10.1124/jpet.102.039651 – start-page: 304 volume-title: Advances in Heterocyclic Chemistry year: 1963 ident: e_1_2_1_2_2 contributor: fullname: Wiseloge FW |
SSID | ssj0009630 |
Score | 1.8570641 |
Snippet | Quinazolines are multitarget agents, which have broad spectrum of biological activity, and some of them are now in cancer clinical testing.... Abstract Quinazolines are multitarget agents, which have broad spectrum of biological activity, and some of them are now in cancer clinical testing.... Quinazolines are multitarget agents, which have broad spectrum of biological activity, and some of them are now in cancer clinical testing. 3-(5-nitro-2-... |
SourceID | proquest crossref pubmed wiley istex |
SourceType | Aggregation Database Index Database Publisher |
StartPage | 519 |
SubjectTerms | Animals apoptosis Apoptosis - drug effects caspase 3 Caspase 3 - metabolism cell cycle Cell Cycle - drug effects cell growth cell growth, cell cycle Cell Line, Tumor Cell Proliferation - drug effects DNA Fragmentation - drug effects Dose-Response Relationship, Drug Enzyme Activation - drug effects Fibroblasts - drug effects Fibroblasts - metabolism L1210 and NIH-3T3 cells Mice Molecular Structure NIH 3T3 Cells quinazoline derivative Quinazolines - chemistry Quinazolines - pharmacology Time Factors Triazoles - chemistry Triazoles - pharmacology |
Title | The effect of 3-(5-nitro-2-thienyl)-9-chloro-5-morpholin-4-yl[1,2,4]triazolo[4,3-c]quinazoline on cell growth, cell cycle, induction of DNA fragmentation, and activity of caspase 3 in murine leukemia L1210 cells and fibroblast NIH-3T3 cells |
URI | https://api.istex.fr/ark:/67375/WNG-G12NRBMX-V/fulltext.pdf https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fcbf.1296 https://www.ncbi.nlm.nih.gov/pubmed/16342136 https://search.proquest.com/docview/20128325 |
Volume | 24 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFDZoiMsLl3ErVyMhBFLSNbbjNo9bR1cQ68O0QaVqimzXXqe2CbSpoHviJ_Ab-SWcEzerhkBCPDh2Ejs-jo_tz5dzDiEvVUsDDGXNUHMXh8LEzRBAvQy1Ui6yxgGkQAHn_Z7sHon3_bi_OlWJsjBeP8T5ghu2jLK_xgau9HxrrTTUaFeHwQq1bUe8iae5dg_WmqOAr1bLKzyUoiUqvbMNtlUlvDASXcGf-u1PMPMiai2Hnc4tMqgI9qdNxvVFoevm7Dddjv9Xotvk5gqN0m3PPnfIZZttkqvePuVyk1xvV-bg7l66BgxF_ekPmjvKf37_8TqGC3QJsxx8Bq4YQUexnLyBYALOjCZ5-Q7jTXOoUbQQBGEBbjkZRAELxDHaDTmDDAciwI-a4y-L0wyfQHlonlHcWqAns_xrMQr8jVkCsQE9zYZe9S3Ss9vbpm6mTqYrWaosoCobUhTbQOsYGMUo6D3nlnJISae4y2DpxC7GUERFP6CKs_Lz8zKhgz-Za5haFLT3rgt08UPuX98jR523h-1uuDIjERreQrZzcRJb03IJeEPBGhCOYEw2uMPYsAA4h7opLJMO5oJSKKMYty7S0iVOA57i98lGlmf2IaGNGGarjuuhTBTgUJOYyBjDmJYykTZRNfKiYqn0s9cWknq90CyF2k2xdmvkVclr5xHUbIyn65px-qm3l-5FrHews99PP9bI84oZU6hrLKLKbL6YpwxRBWdxjTzwPLrOTHLBIo6ZlJz2VyrS9k4H_Uf_GvExuVGuPpVimE_IRjFb2KeAxwr9rGx5vwBa9zxE |
link.rule.ids | 315,783,787,1378,27937,27938,46307,46731 |
linkProvider | Wiley-Blackwell |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFDZjE4wXLuNWbjMSQiAlXWMnbiOeto6ugzYPUweVxhTZrr1NbRNoU0H3xE_gN_JLOCdpVg2BhHhw7CR2fByfY3--nUPIC9lQAENZ3VXcBq6vg7oLoF64SkrrGW0BUuAB524k2of-u37QXyFvyrMwhX6Iiwk3lIy8vUYBxwnpraXWUK1sFXorcZWsgbRzlMrdg6XuKOCsxQQLd4Xf8EvNszW2Vaa81Bet4W_99iegeRm35h1P6xb5VJJc7DcZVmeZqurz37Q5_meZbpObC0BKtwsOukNWTLJBrhUmKucbZL1ZWoS7e-U68BQtNoDQ1FL-8_uPVwFcoFWYpOAzcNkptBXz0WsIhuD06SjN32G8cQqVikaCIOyDm4-OPIc5_jGaDjmHDI98Bz-qj7_MzhJ8AgWiaUJxdYGeTNKv2alT3Og5EOvQs2RQaL9FenajbWon8mS8OE6VOFQmA4onN9BABkbREhrQqaEcUtIxLjQYOjKzIRRR0g5qOcs_P80TWviVqYLRRUaj_TbQxXu8eH2PHLbe9pptd2FJwtW8gZxngzAwumFD8AY-q0HYg25Z4yJjzQDmHKi6b5iwMBwUvtSScWM9JWxoFUAqfp-sJmliHhJaC2DAarkaiFACFNWh9rTWjCkhQmFCWSHPS56KPxcKQ-JCNTSLoXZjrN0KeZkz20UEORniBrt6EH-M9uI9j0UHO91-_KFCNktujKGusYgyMelsGjMEFpwFFfKgYNJlZoL7zOOYSc5qf6Uibu600H_0rxE3yXq71-3Enf3o_WNyI5-Myk9lPiGr2WRmngI8y9SzXAx_Acn-QF0 |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFDawicELl3ErtxkJoSElXWMnbvO4dXQbbBGaNqhUTZHt2OvUNhltKuie-An8Rn4J5yTNqiGQEA-OncSOj-Nj-_PlnEPIa9lSAENZ01XcBq6vg6YLoF64SkrrGW0BUqCA80Ekdo_9992gOz9VibIwpX6IywU3bBlFf40N_DyxGwuloVrZOgxW4gZZ9gVwKgKiw4XqKGCs-foKd4Xf8ivFsw22UaW8MhQt41_99ieceRW2FuNO5y7pVRSXx00G9Wmu6vriN2WO_1eke-TOHI7SzZJ_7pPrJl0lN0sDlbNVcqtd2YN7cG0FOIqWxz9oZin_-f3HegAX6BPGGfgMXN6HnmI2fAvBEJzuD7PiHcYbZVClaCIIwj642bDnOczxT9BwyAVk2PMd_Kg--TI9S_EJlIdmKcW9BXo6zr7mfae80TMg1qFnaVLqvkV6tqNNasfydDQXpkodKtOEotwGmsfAKFpC9zkxlENKOsJtBkOHZjqAIkq6jzrOis9PioQW_mSmYG6R02hvF-jiR7x8_ZAcd94dtXfduR0JV_MW8p0NwsDolg3BS3zWgLAHg7LGLcaGAcSZqKZvmLAwGRS-1JJxYz0lbGgVACr-iCylWWqeENoIYLpquUpEKAGI6lB7WmvGlBChMKGskVcVS8XnpbqQuFQMzWKo3Rhrt0beFLx2GUGOB3i8rhnEn6OdeMdj0eHWQTf-VCNrFTPGUNdYRJmabDqJGcIKzoIaeVzy6CIzwX3mccyk4LS_UhG3tzroP_3XiGtk5eN2J97fiz48I7eLlahCJPM5WcrHU_MCsFmuXhaN8Bf4Cj8M |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+effect+of+3%E2%80%90%285%E2%80%90nitro%E2%80%902%E2%80%90thienyl%29%E2%80%909%E2%80%90chloro%E2%80%905%E2%80%90morpholin%E2%80%904%E2%80%90yl%5B1%2C2%2C4%5Dtriazolo%5B4%2C3%E2%80%90c%5Dquinazoline+on+cell+growth%2C+cell+cycle%2C+induction+of+DNA+fragmentation%2C+and+activity+of+caspase+3+in+murine+leukemia+L1210+cells+and+fibroblast+NIH%E2%80%903T3+cells&rft.jtitle=Cell+biochemistry+and+function&rft.au=Jantov%C3%A1%2C+S.&rft.au=Leta%C5%A1iov%C3%A1%2C+S.&rft.au=Repick%C3%BD%2C+A.&rft.au=Ov%C3%A1dekov%C3%A1%2C+R.&rft.date=2006-11-01&rft.pub=John+Wiley+%26+Sons%2C+Ltd&rft.issn=0263-6484&rft.eissn=1099-0844&rft.volume=24&rft.issue=6&rft.spage=519&rft.epage=530&rft_id=info:doi/10.1002%2Fcbf.1296&rft.externalDBID=10.1002%252Fcbf.1296&rft.externalDocID=CBF1296 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0263-6484&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0263-6484&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0263-6484&client=summon |